Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment

Onkologie

Volumn 27, Issue 1, 2004, Pages 97-104

  Hallek, M ^a   Bergmann, M ^b   Emmerich, B ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chronic lymphatic leukaemia, treatment, diagnosis; Clinical trials; CLL; Fludarabine; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; BENDAMUSTINE; BRYOSTATIN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOXORUBICIN; EPIRUBICIN; FLAVOPIRIDOL; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; MONOCLONAL ANTIBODY; OBLIMERSEN; PHOSPHODIESTERASE INHIBITOR; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE;

BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG RESPONSE; GENETIC ANALYSIS; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGING SYSTEM; IMMUNOPHENOTYPING; INFECTION; LABORATORY TEST; LYMPH NODE; MEASUREMENT; PARAMETER; PROGNOSIS; RADIATION DOSE; REVIEW; RISK ASSESSMENT; SURVIVAL TIME; SYMPTOM; THROMBOCYTOPENIA; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MULTICENTER STUDIES; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 1542617764     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075613     Document Type: Review

References (63)

1. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F: Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 1999;94:448-454.
2. Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS: Familial chronic lymphatic leukemia: A survey and review of published studies. Br J Haematol 2000;109:794-799.
3. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
4. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS: Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-234.
5. Hallek M, Kuhn-Hallek I, Emmerich B: Prognostic factors in chronic lymphocytic leukemia. Leukemia 1997;11(Suppl 2):S4-S13.
6. Zwiebel JA, Cheson BD: Chronic lymphocytic leukemia: Staging and prognostic factors. Semin Oncol 1998;25:42-59.
7. Hallek M, Bergmann M, Emmerich B: Chronische lymphatische Leukämie: Aktualisierte Vorschläge zu Diagnostik und Therapie. Dtsch Ärztebl 2002;99:A1294-A1301.
8. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997.
9. Criel A, Michaux L, De Wolf-Peeters C: The concept of typical and atypical chronic lymphocytic leukaemia. Leuk Lymphoma 1999;33:33-45.
10. Moreau EJ, Matutes E, A'Hern RP, Morilla AM, Morilla RM, Owusu-Ankomah KA, Seon BK, Catovsky D: Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol 1997;108:378-382.
11. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD: The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000;13:193-207.
12. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-1916.
13. Schultze JL, Donovan JW, Gribben JG: Minimal residual disease detection after myeloablative chemotherapy in chronic lymphatic leukemia. J Mol Med 1999;77:259-265.
14. Wilhelm M, Tony HP, Rueckle-Lanz H, Wilms K: First-line therapy of advanced chronic lymphatic leukemia. Leukemia 1997;11(Suppl 2):S14-S18.
15. Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, Mc Credie KB: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991;9:44-49.
16. Keating M: Improving the Complete Remission Rate in Chronic Lymphocytic Leukemia. Hematology 1999. American Society of Hematology educational book, 1999, pp 262-269.
17. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998;92:1165-1171.
18. Angelopoulou MA, Poziopoulos C, Boussiotis VA, Kontopidou F, Pangalis GA: Fludarabine monophosphate in refractory B-chronic lymphocytic leukemia: Maintenance may be significant to sustain response. Leuk Lymphoma 1996;21:321-324.
19. Montserrat E, Lopez-Lorenzo JL, Manso F, Martin A, Prieto E, Arias-Sampedro J, Fernandez MN, Oyarzabal FJ, Odriozola J, Alcala A, Garcia-Conde J, Guardia R, Bosch F: Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: The Spanish Group experience. Leuk Lymphoma 1996;21:467-472.
20. Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD: Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report. J Clin Oncol 1997;15:458-465.
21. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
22. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325.
23. Cheson BD: Therapy for previously untreated chronic lymphocytic leukemia: A reevaluation. Semin Hematol 1998;35:14-21.
24. Anaissie EJ, Kontoyiannis DP, O'Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998;129:559-566.
25. Juliusson G: Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997;39(Suppl 1):S41-S4.
26. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM: Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313-2320.
27. Juliusson G, Christiansen I, Hansen MM, Johnsen S, Kimby E, Elmhorn-Rosenborg A, Liliemark J: Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996;14:2160-2166.
28. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995;13:570-574.
29. Robak T, Blonski JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszynska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P: Cladribine with prednisone versus chlorambucil with prednisone as first- line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood 2000;96:2723-2729.
30. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A, McClure A, Dallaire BK: Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26:66-73.
31. Dyer MJ: The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol 1999;26:52-57.
32. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82.
33. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B and German CLL Study Group: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-1331.
34. O'Brien S, Kantarijan H, Thomas D, Giles F, Freireich E, Cortes J, Lerner S, Keating M: Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J Clin Oncol 2001;19:2165-2170.
35. Byrd J, Murphy T, Howard R, Lucas M, Goodrich A, Pearson M, Waselenko J, Ling G, Grever M, Grillo-Lopez A, Rosenberg J, Kunkel L, Flinn I: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-2164.
36. Kunzmann V, Ruediger T, Hallek M, Mueller-Hermelink HK, Wilhelm M: Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment. Blood 2001;98:1991-1992.
37. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999;94:2217-2224.
38. Tang SC, Hewitt K, Reis MD, Berinstein NL: Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma 1996;24:93-101.
39. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574.
40. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996;93:151-153.
41. Dyer MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, Waldmann H, Newland AC, Catovsky D: In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669-672.
42. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999;94:2836-2843.
43. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M: Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 1997;59:327-328.
44. Hallek M, Schmitt B, Wilhelm M, Emmerich B, Kröber A, Fostitsch HP, Sezer O, Herold M, Knauf W, Busch B, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Döhner H, Thiel E, Hiddemann W, Brittinger C, Emmerich B and Germany CLL Study Group: Fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia: Results of a phase II study (CLL2 protocol) of the German CLL Study Group (GCLLSG). Br J Haematol 2001;114:342-348.
45. O'Brien S, Kantarjian H, Cortes J, Beran M, Koller C, Giles F LE, Lerner S, Keating M: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001;19:1414-1420.
46. Frewin R, Turner D, Tighe M, Davies S, Rule S, Johnson S: Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. Br J Haematol 1999;104:612-613.
47. Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Pianatodosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR: Fludarabine and cyclophosphamide with filgastrim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000;96:71-75.
48. Rummel MJ, Kafer G, Pfreundschuh M, Jager E, Reinhardt U, Mitrou PS, Hoelzer D, Bergmann L: Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study. Ann Oncol 1999;10:183-188.
49. Bosch F, Ferrer A, Lopez-Guillermo A, Gine A, Cobo F, Perales M, Esteve J, Villamor N, Colomer D, Bellosillo B, Ribera JM, Altes A, Besalduch J, Montserrat E: Fludarabine with cyclophosphamide and mitoxantrone (FCM) in resistant or relapsed chronic lymphocytic leukaemia (CLL): Final results of a phase II study. Blood 2001;98(Suppl 1):abstr 2655.
50. Wierda W, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreef M, Cortes J, Faderl S, Thomas D, Koller C, Kantarijan H, Keating M: Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001;98(Suppl 1):abstr 3210.
51. Byrd J, Peterson B, Park K, Morrison V, Vardiman J, Jacobson R, Rai K, Larson R: Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphyocytic leukemia (CLL) patients: Results from CALGB 9712. Blood 2001;98(Suppl 1):abstr 3212.
52. Manero GG, O'Brien S, Cortes J, Faderl S, Giles F, Albitar M, Lerner S, Kantarijan H, Keating M: Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL). Blood 2001;98(Suppl 1):abstr 2650.
53. Schulz H, Klein SH, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A: Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100:3115-3120.
54. Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245-2247.
55. Wendtner CM, Kurzeder C, Kofler D, Edbauer D, Buhmann R, Hallek M: Innovative Therapieansätze; in Hallek M, Emmerich B (Hrsg): Chronische lymphatische Leukämie. Bremen, Uni-Med, 2001, pp 116-122.
56. Byrd JC, Grever MR: Finding new therapies for patients with chronic lymphocytic leukemia; in Cheson B (ed): Chronic Lymphoid Leukemias. New York, NY, Marcel Dekker, Inc. 2001, pp 417-434.
57. Meloni G, Proia A, Mauro F, Amaranto P, Capria S, Cimino G, Cordone I, de Fabritiis P, Rapanotti C, Reato G, Vignetti M, Foa R, Mandelli F: Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: Clinical findings and biological monitoring. Haematologica 2000;85:952-960.
58. Dreger P, Michallet M, Schmitz N: Stem-cell transplantation for chronic lymphocytic leukemia: The 1999 perspective. Ann Oncol 2000;11:49-53.
59. Waselenko JK, Flynn JM, Byrd JC: Stem-cell transplantation in chronic lymphocytic leukemia: The time for designing randomized studies has arrived. Semin Oncol 1999;26:48-61.
60. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R: Transplantlite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998;16:2817-2824.
61. Toze CL, Shepherd JD, Connors JM, Voss NJ, Gascoyne RD, Hogge DE, Klingemann HG, Nantel SH, Nevill TJ, Phillips GL, Reece DE, Sutherland HJ, Barnett MJ: Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant 2000;25:605-612.
62. Gribben JG: Stem-cell transplantation for indolent lymphoma. Semin Hematol 1999;36:18-25.
63. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998;25:80-97.